Factors Influencing Racial and Ethnic Differences in Prescription Opioid Misuse Among Young Adolescents in the USA, 2009-2019.
Epidemiology
Ethnic differences
Opioid misuse
Public health
Race differences
Substance use
Journal
Journal of racial and ethnic health disparities
ISSN: 2196-8837
Titre abrégé: J Racial Ethn Health Disparities
Pays: Switzerland
ID NLM: 101628476
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
03
09
2021
accepted:
22
11
2021
revised:
15
11
2021
pubmed:
1
12
2021
medline:
6
1
2023
entrez:
30
11
2021
Statut:
ppublish
Résumé
Prescription opioid misuse (POM) is an important public health concern. Not many studies have evaluated factors influencing racial and ethnic differences in POM exclusively in young adolescents. We evaluated factors influencing the racial and ethnic differences in POM in a nationally representative sample of 8th- and 10th-grade (12-15 years old) US adolescents. Data were from 107,786 adolescents who participated in the 2009-2019 Monitoring the Future survey. Logistic regression and mediation analysis were used to identify risk factors for POM and evaluate mediators of the association of race and ethnicity on the frequency of POM in the past year. From 2009 to 2019, the prevalence of POM in the past year decreased from 3.2% to 1.8% (p = 0.032), with significant differences in POM trends by race and ethnicity. Overall, the prevalence was higher among non-Hispanic White adolescents (3.2%) than Hispanic (2.5%) and non-Hispanic Black adolescents (1.6%), p < 0.001. After adjustment for demographic, substance use, lifestyle, and family-related factors, the odds of POM were lower among Black (odds ratio (OR) = 0.81, 95% confidence interval (CI): 0.66-0.98) and Hispanic adolescents (OR = 0.64, CI: 0.55-0.74) compared to White adolescents. Illicit drug use and misuse of other prescription drugs together explained 77.2% and 47.3% of the racial and ethnic disparities in POM among Black and Hispanic adolescents, respectively. In this study, significant racial and ethnic differences in the trends of POM were observed. Illicit drug use and misuse of other prescription drugs substantially explained the racial and ethnic disparities in POM among young adolescents.
Sections du résumé
BACKGROUND
Prescription opioid misuse (POM) is an important public health concern. Not many studies have evaluated factors influencing racial and ethnic differences in POM exclusively in young adolescents. We evaluated factors influencing the racial and ethnic differences in POM in a nationally representative sample of 8th- and 10th-grade (12-15 years old) US adolescents.
METHODS
Data were from 107,786 adolescents who participated in the 2009-2019 Monitoring the Future survey. Logistic regression and mediation analysis were used to identify risk factors for POM and evaluate mediators of the association of race and ethnicity on the frequency of POM in the past year.
RESULTS
From 2009 to 2019, the prevalence of POM in the past year decreased from 3.2% to 1.8% (p = 0.032), with significant differences in POM trends by race and ethnicity. Overall, the prevalence was higher among non-Hispanic White adolescents (3.2%) than Hispanic (2.5%) and non-Hispanic Black adolescents (1.6%), p < 0.001. After adjustment for demographic, substance use, lifestyle, and family-related factors, the odds of POM were lower among Black (odds ratio (OR) = 0.81, 95% confidence interval (CI): 0.66-0.98) and Hispanic adolescents (OR = 0.64, CI: 0.55-0.74) compared to White adolescents. Illicit drug use and misuse of other prescription drugs together explained 77.2% and 47.3% of the racial and ethnic disparities in POM among Black and Hispanic adolescents, respectively.
CONCLUSION
In this study, significant racial and ethnic differences in the trends of POM were observed. Illicit drug use and misuse of other prescription drugs substantially explained the racial and ethnic disparities in POM among young adolescents.
Identifiants
pubmed: 34845676
doi: 10.1007/s40615-021-01194-2
pii: 10.1007/s40615-021-01194-2
doi:
Substances chimiques
Prescription Drugs
0
Illicit Drugs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
32-42Informations de copyright
© 2021. W. Montague Cobb-NMA Health Institute.
Références
Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths - United States, 2013–2017. MMWR Morb Mortal Wkly Rep. 2018;67(5152):1419–27. https://doi.org/10.15585/mmwr.mm675152e1 .
doi: 10.15585/mmwr.mm675152e1
Voepel-Lewis T, Boyd CJ, McCabe SE, Zikmund-Fisher BJ, Malviya S, Grant J, et al. Deliberative prescription opioid misuse among adolescents and emerging adults: opportunities for targeted interventions. J Adolesc Health. 2018;63(5):594–600. https://doi.org/10.1016/j.jadohealth.2018.07.007 .
doi: 10.1016/j.jadohealth.2018.07.007
Yaster M, McNaull PP, Davis PJ. The opioid epidemic in pediatrics: a 2020 update. Curr Opin Anaesthesiol. 2020;33(3):327–34. https://doi.org/10.1097/ACO.0000000000000865 .
doi: 10.1097/ACO.0000000000000865
Ford JA. Prescription opioid misuse among adolescents. Pediatr Clin North Am. 2019;66(6):1099–108. https://doi.org/10.1016/j.pcl.2019.08.005 .
doi: 10.1016/j.pcl.2019.08.005
Jones CM, Clayton HB, Deputy NP, Roehler DR, Ko JY, Esser MB, et al. Prescription opioid misuse and use of alcohol and other substances among high school students - Youth Risk Behavior Survey, United States, 2019. MMWR Suppl. 2020;69(1):38–46. https://doi.org/10.15585/mmwr.su6901a5 .
doi: 10.15585/mmwr.su6901a5
Wu LT, Pilowsky DJ, Patkar AA. Non-prescribed use of pain relievers among adolescents in the United States. Drug Alcohol Depend. 2008;94(1–3):1–11. https://doi.org/10.1016/j.drugalcdep.2007.09.023 .
doi: 10.1016/j.drugalcdep.2007.09.023
Sung HE, Richter L, Vaughan R, Johnson PB, Thom B. Nonmedical use of prescription opioids among teenagers in the United States: trends and correlates. J Adolesc Health. 2005;37(1):44–51. https://doi.org/10.1016/j.jadohealth.2005.02.013 .
doi: 10.1016/j.jadohealth.2005.02.013
Ford JA, Rigg KK. Racial/ethnic differences in factors that place adolescents at risk for prescription opioid misuse. Prev Sci. 2015;16(5):633–41. https://doi.org/10.1007/s11121-014-0514-y .
doi: 10.1007/s11121-014-0514-y
Gallimberti L, Buja A, Chindamo S, Lion C, Terraneo A, Marini E, et al. Prevalence of substance use and abuse in late childhood and early adolescence: what are the implications? Prev Med Rep. 2015;2:862–7. https://doi.org/10.1016/j.pmedr.2015.09.018 .
doi: 10.1016/j.pmedr.2015.09.018
Cerdá M, Santaella J, Marshall BDL, Kim JH, Martins SS. Nonmedical prescription opioid use in childhood and early adolescence predicts transitions to heroin use in young adulthood: a national study. J Pediatr. 2015;167(3):605-12.e2. https://doi.org/10.1016/j.jpeds.2015.04.071 .
doi: 10.1016/j.jpeds.2015.04.071
Monitoring the Future Study: trends in prevalence of various drugs. https://www.drugabuse.gov/trends-statistics/monitoring-future/monitoring-future-study-trends-in-prevalence-various-drugs (2019). Accessed August 8, 2021.
Jordan AE, Blackburn NA, Des Jarlais DC, Hagan H. Past-year prevalence of prescription opioid misuse among those 11 to 30years of age in the United States: a systematic review and meta-analysis. J Subst Abuse Treat. 2017;77:31–7. https://doi.org/10.1016/j.jsat.2017.03.007 .
doi: 10.1016/j.jsat.2017.03.007
Miech RA, Johnston LD, Bachman JG, O'Malley PM, Schulenberg JE, Patrick ME. Monitoring the Future: a continuing study of American youth (8th- and 10th-grade surveys), 2019. Inter-university Consortium for Political and Social Research [distributor]; 2020.
Johnston L, Miech R, O'Malley P, Bachman J, Schulenberg J, Patrick M: Demographic subgroup trends among adolescents in the use of various licit and illicit drugs, 1975–2019 (Monitoring the Future occasional paper no. 94). https://deepblue.lib.umich.edu/handle/2027.42/162581 (2020). Accessed November 10, 2021.
Hayes AF. Introduction to mediation, moderation, and conditional process analysis: a regression-based approach. 2nd ed. Methodology in the social sciences. New York, NY: The Guilford Press; 2018.
Centers for Disease Control and Prevention: 2018 annual surveillance report of drug-related risks and outcomes — United States. Surveillance special report. https://stacks.cdc.gov/view/cdc/58547 (2018). Accessed November 12, 2021.
Substance Abuse and Mental Health Services Administration (SAMHSA). Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health. In: U.S. Department of Health and Human Services (HHS), editor. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2017.
Schepis TS, Teter CJ, McCabe SE. Prescription drug use, misuse and related substance use disorder symptoms vary by educational status and attainment in U.S. adolescents and young adults. Drug Alcohol Depend. 2018;189:172–7. https://doi.org/10.1016/j.drugalcdep.2018.05.017 .
doi: 10.1016/j.drugalcdep.2018.05.017
Hudgins JD, Porter JJ, Monuteaux MC, Bourgeois FT. Prescription opioid use and misuse among adolescents and young adults in the United States: a national survey study. PLoS Med. 2019;16(11):e1002922. https://doi.org/10.1371/journal.pmed.1002922 .
doi: 10.1371/journal.pmed.1002922
Martins SS, Segura LE, Santaella-Tenorio J, Perlmutter A, Fenton MC, Cerda M, et al. Prescription opioid use disorder and heroin use among 12–34 year-olds in the United States from 2002 to 2014. Addict Behav. 2017;65:236–41. https://doi.org/10.1016/j.addbeh.2016.08.033 .
doi: 10.1016/j.addbeh.2016.08.033
Boyd CJ, Esteban McCabe S, Teter CJ. Medical and nonmedical use of prescription pain medication by youth in a Detroit-area public school district. Drug Alcohol Depend. 2006;81(1):37–45. https://doi.org/10.1016/j.drugalcdep.2005.05.017 .
doi: 10.1016/j.drugalcdep.2005.05.017
Griesler PC, Hu MC, Wall MM, Kandel DB. Assessment of prescription opioid medical use and misuse among parents and their adolescent offspring in the US. JAMA Netw Open. 2021;4(1):e2031073. https://doi.org/10.1001/jamanetworkopen.2020.31073 .
doi: 10.1001/jamanetworkopen.2020.31073
Nichols LM, Pedroza JA, Fleming CM, O’Brien KM, Tanner-Smith EE. Social-ecological predictors of opioid use among adolescents with histories of substance use disorders. Front Psychol. 2021;12:686414. https://doi.org/10.3389/fpsyg.2021.686414 .
doi: 10.3389/fpsyg.2021.686414
Phan MT, Tomaszewski DM, Arbuckle C, Yang S, Donaldson C, Fortier M, et al. Racial and ethnic disparities in opioid use for adolescents at US emergency departments. BMC Pediatr. 2021;21(1):252. https://doi.org/10.1186/s12887-021-02715-y .
doi: 10.1186/s12887-021-02715-y
McCance-Katz EF: The National Survey on Drug Use and Health: 2018. https://www.samhsa.gov/data/release/2018-national-survey-drug-use-and-health-nsduh-releases (2019). Accessed November 12, 2021.
Hughes A, Williams MR, Lipari RN, Bose J, Copello EAP, Kroutil LA: Prescription drug use and misuse in the United States: results from the 2015 National Survey on Drug Use and Health. NSDUH data review. https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR2-2015/NSDUH-FFR2-2015.htm (2016). Accessed November 13, 2021.
Nicholson HL, Ford JA. Correlates of prescription opioid misuse among Black adults: findings from the 2015 National Survey on Drug Use and Health. Drug Alcohol Depend. 2018;186:264–7. https://doi.org/10.1016/j.drugalcdep.2017.12.006 .
doi: 10.1016/j.drugalcdep.2017.12.006
The Substance Abuse and Mental Health Services Administration (SAMHSA): The National Survey on Drug Use and Health (NSDUH). https://nsduhweb.rti.org/respweb/about_nsduh.html (2021). Accessed November 13, 2021.
McCabe SE, Teter CJ, Boyd CJ, Wilens TE, Schepis TS. Sources of prescription medication misuse among young adults in the United States: the role of educational status. J Clin Psychiatry. 2018;79(2). https://doi.org/10.4088/JCP.17m11958 .
McCabe SE, West BT, Schepis TS, Teter CJ. Simultaneous co-ingestion of prescription stimulants, alcohol and other drugs: a multi-cohort national study of US adolescents. Hum Psychopharmacol. 2015;30(1):42–51. https://doi.org/10.1002/hup.2449 .
doi: 10.1002/hup.2449
McCabe SE, Veliz PT, Boyd CJ, Schepis TS, McCabe VV, Schulenberg JE. A prospective study of nonmedical use of prescription opioids during adolescence and subsequent substance use disorder symptoms in early midlife. Drug Alcohol Depend. 2019;194:377–85. https://doi.org/10.1016/j.drugalcdep.2018.10.027 .
doi: 10.1016/j.drugalcdep.2018.10.027
Alinsky RH, Zima BT, Rodean J, Matson PA, Larochelle MR, Adger H Jr, et al. Receipt of addiction treatment after opioid overdose among Medicaid-enrolled adolescents and young adults. JAMA Pediatr. 2020;174(3):e195183. https://doi.org/10.1001/jamapediatrics.2019.5183 .
doi: 10.1001/jamapediatrics.2019.5183
Martins SS, Segura LE, Santaella-Tenorio J, Perlmutter A, Fenton MC, Cerdá M, et al. Prescription opioid use disorder and heroin use among 12–34 year-olds in the United States from 2002 to 2014. Addict Behav. 2017;65:236–41. https://doi.org/10.1016/j.addbeh.2016.08.033 .
doi: 10.1016/j.addbeh.2016.08.033
Henke RM, Tehrani AB, Ali MM, Mutter R, Mazer-Amirshahi M, O’Brien PL. et al Opioid prescribing to adolescents in the United States from 2005 to 2016. Psychiatr Serv. 2018;69(9):1040–3.
doi: 10.1176/appi.ps.201700562
Gaither JR, Leventhal JM, Ryan SA, Camenga DR. National trends in hospitalizations for opioid poisonings among children and adolescents, 1997 to 2012. JAMA Pediatr. 2016;170(12):1195–201. https://doi.org/10.1001/jamapediatrics.2016.2154 .
doi: 10.1001/jamapediatrics.2016.2154
Curtin SC, Tejada-Vera B, Warmer M. Drug overdose deaths among adolescents aged 15–19 in the United States: 1999–2015. NCHS Data Brief. 2017;282:1–8.
Medication for adolescents and young adults with opioid use disorder. J Adolesc Health. 2021;68(3):632–6. https://doi.org/10.1016/j.jadohealth.2020.12.129 .
Committee On Substance Use and Prevention. Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics. 2016;138(3). https://doi.org/10.1542/peds.2016-1893 .
Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiat. 2019;76(9):979–81. https://doi.org/10.1001/jamapsychiatry.2019.0876 .
doi: 10.1001/jamapsychiatry.2019.0876
Schuler MS, Dick AW, Stein BD. Growing racial/ethnic disparities in buprenorphine distribution in the United States, 2007–2017. Drug Alcohol Depend. 2021;223:108710. https://doi.org/10.1016/j.drugalcdep.2021.108710 .
doi: 10.1016/j.drugalcdep.2021.108710
Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001–2014. JAMA Pediatr. 2017;171(8):747–55. https://doi.org/10.1001/jamapediatrics.2017.0745 .
doi: 10.1001/jamapediatrics.2017.0745
Abraham AJ, Adams GB, Bradford AC, Bradford WD. County-level access to opioid use disorder medications in Medicare part D (2010–2015). Health Serv Res. 2019;54(2):390–8. https://doi.org/10.1111/1475-6773.13113 .
doi: 10.1111/1475-6773.13113
Parran TV, Muller JZ, Chernyak E, Adelman C, Delos Reyes CM, Rowland D, et al. Access to and payment for office-based buprenorphine treatment in Ohio. Subst Abuse. 2017;11:1178221817699247. https://doi.org/10.1177/1178221817699247 .
doi: 10.1177/1178221817699247
Cummings JR, Wen H, Ko M, Druss BG. Race/ethnicity and geographic access to medicaid substance use disorder treatment facilities in the United States. JAMA Psychiat. 2014;71(2):190–6. https://doi.org/10.1001/jamapsychiatry.2013.3575 .
doi: 10.1001/jamapsychiatry.2013.3575
Toce MS, Michelson K, Hudgins J, Burns MM, Monuteaux MC, Bourgeois FT. Association of state-level opioid-reduction policies with pediatric opioid poisoning. JAMA Pediatr. 2020;174(10):961–8. https://doi.org/10.1001/jamapediatrics.2020.1980 .
doi: 10.1001/jamapediatrics.2020.1980
Bagley SM, Chavez L, Braciszewski JM, Akolsile M, Boudreau DM, Lapham G, et al. Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems. Addict Sci Clin Pract. 2021;16(1):46. https://doi.org/10.1186/s13722-021-00249-3 .
doi: 10.1186/s13722-021-00249-3
Weintraub E, Seneviratne C, Anane J, Coble K, Magidson J, Kattakuzhy S, et al. Mobile telemedicine for buprenorphine treatment in rural populations with opioid use disorder. JAMA Netw Open. 2021;4(8):e2118487-e. https://doi.org/10.1001/jamanetworkopen.2021.18487 .
doi: 10.1001/jamanetworkopen.2021.18487
Franz B, Dhanani LY, Miller WC. Rural-urban differences in physician bias toward patients with opioid use disorder. Psychiatr Serv. 2021;72(8):874–9. https://doi.org/10.1176/appi.ps.202000529 .
doi: 10.1176/appi.ps.202000529
McCabe SE, West BT, Boyd CJ. Leftover prescription opioids and nonmedical use among high school seniors: a multi-cohort national study. J Adolesc Health. 2013;52(4):480–5. https://doi.org/10.1016/j.jadohealth.2012.08.007 .
doi: 10.1016/j.jadohealth.2012.08.007
McCabe SE, West BT, Veliz P, McCabe VV, Stoddard SA, Boyd CJ. Trends in medical and nonmedical use of prescription opioids among US adolescents: 1976–2015. Pediatrics. 2017;139(4):e20162387. https://doi.org/10.1542/peds.2016-2387 .
doi: 10.1542/peds.2016-2387
Lipari RN, Hughes A. How people obtain the prescription pain relievers they misuse. The CBHSQ report. Rockville (MD). 2013; 1–7. https://www.samhsa.gov/data/sites/default/files/report_2686/ShortReport-2686.html . Accessed 13 Nov 2021.